Pantoprazole sodium NDC 27241-256

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-256Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0256Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-256-11	27241025611	1 FOR SUSPENSION in 1 PACKET (27241-256-11)Marketed from Feb 9, 2023
27241-256-38	27241025638	30 FOR SUSPENSION in 1 CARTON (27241-256-38)Marketed from Feb 9, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pantoprazole sodium
Generic name (nonproprietary): pantoprazole sodium
Active ingredients: Pantoprazole sodium — 40 mg/1
Dosage form: For suspension
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217416
Marketing start: Feb 9, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Proton Pump Inhibitors (Mechanism)
Identifiers: Product ID 27241-256_d0fe5d1b-fb0c-4c7b-af8b-cda49f2c8f7eSPL ID d0fe5d1b-fb0c-4c7b-af8b-cda49f2c8f7eSPL set ID 90963a38-f629-45a4-bddd-9e13a55fe0f7RxCUI 763306UNII 6871619Q5X
Pharmacologic class: Proton Pump Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241025611 followed by a unit qualifier and the quantity

Package 27241-0256-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 26, 2025.

Indications (excerpt from the label)

Pantoprazole sodium for delayed-release oral suspension is indicated for: Pantoprazole sodium for delayed-release oral suspension is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium for delayed-release oral suspension is indicated in adults and pediatric patients five years of age and older for the short-term treatm…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217416

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217416
Product	Strength	Form · route	Labeler	Product NDC
Pantoprazole sodium	Pantoprazole sodium 40 mg/1	For suspensionOral	American Health Packaging	60687-767